Pipeline programs OX640 and Izipry advanced toward pivotal milestones, with key trials and regulatory submissions on track for late 2026 and early 2027. Financials reflect lower revenues, increased legal and restructuring costs, and a need for additional financing to support ongoing development and resolve the DOJ investigation.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.